In another study, immunosuppressive triggering receptor expressed on myeloid cells 2 (TREM-2), a glycosylated receptor belonging to the immunoglobulin superfamily (IgSF) [528], expressed by TAMs phenotype was also detected in clinical specimens of NSCLC patients and linked to T cell function inhibition, including diminished anti-tumor activity of CD8+ T cells and enhanced differentiation toward FOXP3+ Tregs [529]. The gene discussed is CD8A; the disease is neoplasm.